Novel Brain Targeting Prodrugs of Naproxen Based on Dimethylamino Group with Various Linkages

Q. Zhang; Z. Liang; L. Y. Chen; X. Sun; T. Gong; Z. R. Zhang

doi:10.1055/s-0032-1306273

Arzneimittelforschung, Table of Contents

Arzneimittelforschung 2012; 62(06): 261-266
DOI: 10.1055/s-0032-1306273

Original Article

Novel Brain Targeting Prodrugs of Naproxen Based on Dimethylamino Group with Various Linkages

Q. Zhang

¹Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, People’s Republic of China

,

Z. Liang

¹Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, People’s Republic of China

,

L. Y. Chen

¹Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, People’s Republic of China

,

X. Sun

¹Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, People’s Republic of China

,

T. Gong

¹Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, People’s Republic of China

,

Z. R. Zhang

¹Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, People’s Republic of China

› Author Affiliations

Abstract

As a preventive and treatment drug for Alzheimer's disease (AD), naproxen’s clinical application is hampered by its limited distribution in the brain. To increase the delivery of naproxen across the blood–brain barrier (BBB), 3 prodrugs (P1, P2 and P3) of naproxen were synthesized through either ester bond or amido bond using the dimethylamino moiety as a brain-targeting ligand. The in vitro release of naproxen from the 3 prodrugs was studied in PBS, rat plasma and brain homogenate. P3 with an amido bond appeared to be highly stable in all incubation media, whereas P1 and P2 with ester bonds were partially hydrolyzed in alkaline environment and brain homogenate to yield the parent drug. After i. v. administration to rats, the brain concentration of total naproxen (summation of released and bound naproxen, TN) of P1, P2 and P3 groups were 28.81, 24.51 and 15.54 times greater than that of the control naproxen group at 5 min, respectively, and the brain AUC_0–t were 6.94, 10.06 and 6.70 times greater than that of the control naproxen group. In addition, the C_max of TN in the brain after the administration of prodrugs with ester bonds (P1 and P2) was higher than that of the amide prodrug (P3). The results highlighted the possibility of brain delivery of naproxen using prodrug strategies based on the brain-targeting ligand with dimethylamino moiety, in which the linkage between drug and targeting group might play an important role in modulating the in vivo behaviors of these prodrugs.

Key words

naproxen - dimethylamino group - drug design - brain targeting - prodrugs - Alzheimer’s disease (AD)

Full Text

References

References
1 Patel PM, Drummond JC, Sano T et al. Effect of ibuprofen on regional eicosanoid production and neuronal injury after forebrain ischemia in rats. Brain Res 1993; 614: 316-324
2 Silakova JM, Hewett JA, Hewett SJ. Naproxen reduces excitotoxic neurodegeneration in vivo with an extended therapeutic window. J Pharmacol Exp Ther 2004; 309: 1060-1066
3 Szekely CA, Thorne JE, Zandi PP et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 2004; 23: 159-169
4 Gasparini L, Ongini E, Wenk G. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer’s disease: old and new mechanisms of action. J Neurochem 2004; 91: 521-536
5 Hirohata M, Ono K, Naiki H et al. Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer’s beta-amyloid fibrils in vitro. Neuropharmacology 2005; 49: 1088-1099
6 Rainsford KD, Schweitzer A, Brune K. Autoradiographic and biochemical observations on the distribution of non-steroid anti-inflammatory drugs. Arch Int Pharmacodyn Ther 1981; 250: 180-194
7 Brune K, Neubert A. Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a pharmacologist’s perspective. Clin Exp Rheumatol 2001; 19 (Suppl. 25) S51-S57
8 Eriksen JL, Sagi SA, Smith TE et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 2003; 112: 440-449
9 Marchal-Heussler L, Maincent P, Hoffman M et al. Antiglaucomatous activity of betaxolol chlorhydrate sorbed onto different isobutylcyanoacrylate nanoparticle preparations. Int J Pharm 1990; 58: 115-122
10 Chen Q, Gong T, Liu J et al. Synthesis, in vitro and in vivo characterization of glycosyl derivatives of ibuprofen as novel prodrugs for brain drug delivery. J Drug Target 2009; 17: 318-328
11 Saavedra JE, Billiar TR, Williams DL et al. Targeting nitric oxide (NO) delivery in vivo. Design of a liver-selective NO donor prodrug that blocks tumor necrosis factor-α-induced apoptosis and toxicity in the liver. J Med Chem 1997; 40: 1974-1954
12 Valckenborgh EV, Mincher D, Salvo AD et al. Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model. Leukemia 2005; 19: 1628-1633
13 Zhang X, Liu X, Gong T et al. In vitro and in vivo study of dexibuprofen derivatives for CNS delivery. Acta Pharmacol Sin 2012; 33: 279-288
14 Buchwald P, Bodor N. Quantitative structure-metabolism relationships: steric and nonsteric effects in the enzymatic hydrolysis of noncongener carboxylic esters. J Med Chem 1999; 42: 5160-5168
15 Larsen C, Johansen M. Macromolecular prodrugs I. Kinetics and mechanism of hydrolysis of O-benzoyl dextran conjugates in aqueous buffer and in human plasma. Int J Pharm 1985; 27: 205-218
16 Ettmayer P, Amidon GL, Clement B et al. Lessons learned from marketed and investigational prodrugs. J Med Chem 2004; 47: 2393-2404
17 Chang CS, Tsai SW. A facile enzymatic process for the preparation of (S)-Naproxen ester prodrug in organic solvents. Enzyme Microb Tech 1997; 20: 635-639
18 Halmos T, Santarromana M, Antonakis K et al. Synthesis of glucose-chlorambucil derivatives and their recognition by the human GLUT1 glucose transporter. Eur J Pharmacol 1996; 318: 477-484
19 Jagan Mohan R, Parepally JMR, Mandula H et al. Brain uptake of nonsteroidal anti-inflammatory drugs: ibuprofen, flurbiprofen, and indomethacin. Pharm Res 2006; 23: 873-881
20 Kalgutkar AS, Crews BC, Rowlinson SW et al. Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: Facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. PNAS 2000; 97: 925-930
21 Duﬂos M, Nourrisson MR, Brelet J et al. PetitN-Pyridinyl-indole-3-(alkyl)carboxamides and derivatives as potential systemic and topical inﬂammation inhibitors. Eur J Med Chem 2001; 36: 545-553
22 Labanauskas L, Udrenaite E, Gaidelis P et al. Synthesis of 5-(2-,3- and 4-methoxyphenyl)-4H-1,2,4-triazole-3-thiol derivatives exhibiting anti-inﬂammatory activity. Farmaco 2004; 59: 255-259
23 Barsoum F, Georgey H, Abdel-Gawad N. Anti-inflammatory activity and PGE2 inhibitory properties of novel phenylcarbamoylmethyl ester-containing compounds. Molecules 2009; 14: 667-681
24 Halen PK, Murumkar PR, Giridhar R et al. Synthesis, hydrolysis studies and phamacodynamic profiles of amide prodrugs of dexibuprofen with amino acids. Mini-rev Med Chem 2009; 9: 124-139
25 Amir M, Kumar H, Javed SA. Synthesis and pharmacological evaluation of condensed heterocyclic 6-substituted-1, 2, 4-triazolo [3, 4-b]-1, 3, 4-thiadiazole derivatives of naproxen. Bioorg Med Chem Lett 2007; 17: 4504-4508